| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00072540 Details | 2013-11-08 Interventional | 2 | 0 | Celecoxib Enzyme Inhibito… Mitogens Carcinoma in Si… Carcinoma, Squa… Squamous Intrae… High-grade Squa… Stage 0 Cervica… | drug issues - | |||
| NCT00680563 Details | 2013-11-05 Interventional | 3 | 4 | Epoetin Alfa Anemia | - - | |||
| NCT01203618 Details | 2013-11-03 Interventional | 2 | 0 | Farletuzumab Adenoma Pituitary Disea… Pituitary Neopl… Resectable, Non… | Trial terminated due to focus of primary therapeutic areas. - | |||
| NCT00514917 2007-000323-17 Details | 2013-11-03 Interventional | 3 | 413 | Bicalutamide Docetaxel Leuprolide Prostatic Neopl… | Company decision to discontinue the study, not due to any safety or efficacy concerns - | |||
| NCT00274105 Details | 2013-11-01 Interventional | 4 | - | Telmisartan Arteriosclerosi… Coronary Artery… Myocardial Isch… Coronary Arteri… Hypertension | - - | |||
| NCT01973504 Details | 2013-10-31 Interventional | 2 | 0 | Chrysarobin Acidosis Acidosis, Lacti… Shock Shock, Hemorrha… Wounds and Inju… Hemorrhagic Sho… Lactic Acidosis Trauma | Sangart ceased operations - | |||
| NCT00365183 Details | 2013-10-31 Interventional | 2 | 74 | Motexafin gadol… Pemetrexed Carcinoma Carcinoma, Non-… Lung Neoplasms Non-Small Cell … | - - | |||
| NCT00168792 Details | 2013-10-29 Interventional | 4 | [1 Refs] | - | Tenecteplase Infarction Myocardial Infa… | - - | ||
| NCT00157261 Details | 2013-10-29 Interventional | 3 | - | Tenecteplase Heart Arrest | - - | |||
| NCT01925001 Details | 2013-10-28 Interventional | 2 | 0 | Pharmaceutical … Anemia Anemia, Sickle … Hemoglobin C Di… Hemoglobin SC D… Sickle Cell Ane… Sickle Cell Dis… Sickle Cell Dis… Sickle Cell Hem… | Sangart ceased operations - | |||
| NCT00961207 Details | 2013-10-28 Interventional | 4 | 2 | Aliskiren Albuminuria Diabetic Nephro… Proteinuria Diabetes Macroalbuminuri… Microalbuminuri… | Altitude trial which used similar drugs was terminated due to increased ADR. - | |||
| NCT01312454 Details | 2013-10-25 Interventional | 2 | 4 | Pharmaceutical … Travoprost Glaucoma Glaucoma, Open-… Hypertension Ocular Hyperten… Open-angle Glau… | Management decision - | |||
| NCT00719199 Details | 2013-10-22 Interventional | 1 | 21 | Cetuximab Colorectal Neop… Colorectal Canc… | Sponsor will discontinue further development of EMD 1201081 - | |||
| NCT01061853 2007-000152-14 Details | 2013-10-16 Interventional | 3 | 76 | Betamethasone Sirolimus Lichen Planus Lichen Planus, … Oral Lichen Pla… | Per protocol intermediate analyses of 76 patients and enrollment difficulties. - | |||
| NCT01526174 Details | 2013-10-14 Interventional | 1/2 | 16 | Golimumab Ear Diseases Labyrinth Disea… Labyrinthitis Autoimmune Inne… | House Research no longer conducting research. - | |||
| NCT01648699 Details | 2013-10-11 Interventional | 4 | 20 | Hydromorphone Cancer Pain Pain | the study was stopped due to non-availability of 4mg The study was prematurely terminated due to administrative reason. | |||
| NCT00110344 Details | 2013-10-11 Interventional | 2 | 1 | Sorafenib Carcinoma Carcinoma, Rena… | - - | |||
| NCT01896440 Details | 2013-10-08 Interventional | 4 | 0 | Ondansetron Neoplasms Malignant Child… | FDA did not approve - | |||
| NCT01741142 Details | 2013-10-08 Interventional | 2 | 19 | Escitalopram Depression Depressive Diso… Depressive Diso… Major Depressiv… | Decision based on strategic determination; not safety. - | |||
| NCT00243035 Details | 2013-10-08 Interventional | 1/2 | - | Bortezomib Tipifarnib Multiple Myelom… Neoplasms, Plas… Refractory Mult… Stage II Multip… Stage III Multi… | - - |